Hepatitis Forums

Hepatitis C Main Forums => Hepatitis C and HIV Coinfection => Topic started by: iana5252 on March 09, 2014, 03:28:16 pm

Title: Merck’s Hep C Drugs Show Promise for HIV Coinfection
Post by: iana5252 on March 09, 2014, 03:28:16 pm

Promising preliminary results from a trial of Merck’s MK-5172 and MK-8742, given with or without ribavirin, showed the combination therapy was as safe in treating genotype 1 of hepatitis C virus (HCV) among those coinfected with HIV as it was among those monoinfected with hep C. The treatment appears to boast near-perfect success rates. Results from the C-WORTHY study, which is a Phase II, randomized, dose-responsive, parallel-group, multiple-site, open-label trial comparing various difficult-to-treat populations among a group of 450 people with hep C, were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.

The coinfected segment of the study included 59 people coinfected with HIV and genotype 1 of HCV who were treatment naive, did not have cirrhosis and who were taking a stable antiretroviral regimen to treat HIV.

Read more...
http://www.hepmag.com/articles/Merck_coinfected_2501_25254.shtml

Title: Re: Merck’s Hep C Drugs Show Promise for HIV Coinfection
Post by: lporterrn on March 09, 2014, 03:36:24 pm

Isn't this amazing! I thought this year's CROI provided the most reasons for optimism ever! http://www.croi2014.org/ (http://www.croi2014.org/)